Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02824003 | Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes | PHASE2 | COMPLETED | 15 | — | — | Apr 1, 2016 | May 22, 2017 | May 8, 2018 | 1 | Austria |
Change from Baseline
Change from Baseline
| Arm | Type | Description |
|---|---|---|
| ISIS-GCGRRx | EXPERIMENTAL | ISIS-GCGRRx once weekly dosing for 13 weeks |
| Placebo | PLACEBO_COMPARATOR | once weekly dosing for 13 weeks |
| Name | Type | Description |
|---|---|---|
| ISIS-GCGRRx | DRUG | once weekly dosing for 13 weeks |
| Placebo | DRUG | once weekly dosing for 13 weeks |
Inclusion Criteria: * Male or female, age 18 to 75 * BMI ≥ 25.0 kg/m2 \< 36.0 kg/m2 * HbA1c ≥ 7.5% and ≤ 10.5% * Type 2 Diabetes Mellitus and on stable dose of Metformin. Patients must have been on a stable dose of oral metformin (at least 1000 mg/day) for a minimum of 3 months prior to screening e...